Teva And Celltrion Gain Arthritis Advantage On Rituximab

Truxima Biosimilar Now Available In Rheumatoid Arthritis Indication In US

 
• By Akriti Seth and Dave Wallace

Teva and Celltrion’s Truxima rituximab biosimilar is now available with a rheumatoid arthritis indication in the US, the firms have revealed, giving it a potential advantage over Pfizer’s Ruxience version.

Watch_Face_Advantage
Teva is aiming to take advantage of its exclusive indication for its rituximab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products